BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8642567)

  • 1. Probes for narcotic receptor-mediated phenomena. 21. Novel derivatives of 3-(1,2,3,4,5,11-hexahydro-3-methyl-2,6-methano-6H-azocino[4,5-b]indol- 6-yl)-phenols with improved delta opioid receptor selectivity.
    Bertha CM; Ellis M; Flippen-Anderson JL; Porreca F; Rothman RB; Davis P; Xu H; Becketts K; Rice KC
    J Med Chem; 1996 May; 39(10):2081-6. PubMed ID: 8642567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists.
    Katsura Y; Zhang X; Homma K; Rice KC; Calderon SN; Rothman RB; Yamamura HI; Davis P; Flippen-Anderson JL; Xu H; Becketts K; Foltz EJ; Porreca F
    J Med Chem; 1997 Aug; 40(18):2936-47. PubMed ID: 9288176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective delta agonist (+)-4-[(alpha R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]- N,N-diethylbenzamide (SNC 80) and related novel nonpeptide delta opioid receptor ligands.
    Calderon SN; Rice KC; Rothman RB; Porreca F; Flippen-Anderson JL; Kayakiri H; Xu H; Becketts K; Smith LE; Bilsky EJ; Davis P; Horvath R
    J Med Chem; 1997 Feb; 40(5):695-704. PubMed ID: 9057856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
    Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
    J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
    Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
    J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
    Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
    J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the delta-opioid receptor.
    Liao S; Alfaro-Lopez J; Shenderovich MD; Hosohata K; Lin J; Li X; Stropova D; Davis P; Jernigan KA; Porreca F; Yamamura HI; Hruby VJ
    J Med Chem; 1998 Nov; 41(24):4767-76. PubMed ID: 9822547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid profiles of Cys2-containing enkephalin analogues.
    Pencheva N; Milanov P; Vezenkov L; Pajpanova T; Naydenova E
    Eur J Pharmacol; 2004 Sep; 498(1-3):249-56. PubMed ID: 15364002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro potency, affinity and agonist efficacy of highly selective delta opioid receptor ligands.
    Kramer TH; Davis P; Hruby VJ; Burks TF; Porreca F
    J Pharmacol Exp Ther; 1993 Aug; 266(2):577-84. PubMed ID: 8394911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors.
    Knapp RJ; Santoro G; De Leon IA; Lee KB; Edsall SA; Waite S; Malatynska E; Varga E; Calderon SN; Rice KC; Rothman RB; Porreca F; Roeske WR; Yamamura HI
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1284-91. PubMed ID: 8667189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism.
    Balboni G; Salvadori S; Guerrini R; Negri L; Giannini E; Bryant SD; Jinsmaa Y; Lazarus LH
    J Med Chem; 2004 Jul; 47(16):4066-71. PubMed ID: 15267245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile.
    Tourwé D; Mannekens E; Diem TN; Verheyden P; Jaspers H; Tóth G; Péter A; Kertész I; Török G; Chung NN; Schiller PW
    J Med Chem; 1998 Dec; 41(26):5167-76. PubMed ID: 9857087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
    Tóth G; Ioja E; Tömböly C; Ballet S; Tourwé D; Péter A; Martinek T; Chung NN; Schiller PW; Benyhe S; Borsodi A
    J Med Chem; 2007 Jan; 50(2):328-33. PubMed ID: 17228874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of 1-aminocycloalkane-1-carboxylic acid-substituted deltorphin analogues: unique delta and mu opioid activity in modified peptides.
    Breveglieri A; Guerrini R; Salvadori S; Bianchi C; Bryant SD; Attila M; Lazarus LH
    J Med Chem; 1996 Feb; 39(3):773-80. PubMed ID: 8576920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of aromatic amino acid substitutions in the 3-position of cyclic beta-casomorphin analogues on mu-opioid agonist/delta-opioid antagonist properties.
    Schmidt R; Wilkes BC; Chung NN; Lemieux C; Schiller PW
    Int J Pept Protein Res; 1996 Nov; 48(5):411-9. PubMed ID: 8956074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subsensitivity to opioids is receptor-specific in isolated guinea pig ileum and mouse vas deferens after obstructive cholestasis.
    Dehpour AR; Rastegar H; Jorjani M; Roushanzamir F; Joharchi K; Ahmadiani A
    J Pharmacol Exp Ther; 2000 Jun; 293(3):946-51. PubMed ID: 10869396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
    Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
    Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-(alphaR)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-alkyl-N-arylbenzamides: potent, non-peptidic agonists of both the micro and delta opioid receptors.
    Bishop MJ; Garrido DM; Boswell GE; Collins MA; Harris PA; McNutt RW; O'Neill SJ; Wei K; Chang KJ
    J Med Chem; 2003 Feb; 46(4):623-33. PubMed ID: 12570383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynorphin A(1-8): stability and implications for in vitro opioid activity.
    Bell KM; Traynor JR
    Can J Physiol Pharmacol; 1998 Mar; 76(3):325-33. PubMed ID: 9673796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.